-
Something wrong with this record ?
Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target
V. Krystof, S. Baumli, R. Fürst,
Language English Country Netherlands
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Cyclin-Dependent Kinase 9 antagonists & inhibitors metabolism MeSH
- Protein Kinase Inhibitors pharmacology MeSH
- Drug Delivery Systems MeSH
- Humans MeSH
- Neoplasms drug therapy enzymology MeSH
- Antineoplastic Agents pharmacology MeSH
- Drug Design MeSH
- Inflammation enzymology pathology MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13000830
- 003
- CZ-PrNML
- 005
- 20130109113154.0
- 007
- ta
- 008
- 130108s2012 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2174/138161212800672750 $2 doi
- 035 __
- $a (PubMed)22571657
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Krystof, Vladimír $u Laboratory of Growth Regulators, Palacký University, Šlechtitelů 11, 78371, Olomouc, Czech Republic. vladimir.krystof@upol.cz
- 245 10
- $a Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target / $c V. Krystof, S. Baumli, R. Fürst,
- 520 9_
- $a Deregulation of cyclin-dependent kinases (CDKs) has been associated with many cancer types and has evoked an interest in chemical inhibitors with possible therapeutic benefit. While most known inhibitors display broad selectivity towards multiple CDKs, recent work highlights CDK9 as the critical target responsible for the anticancer activity of clinically evaluated drugs. In this review, we discuss recent findings provided by structural biologists that may allow further development of highly specific inhibitors of CDK9 towards applications in cancer therapy. We also highlight the role of CDK9 in inflammatory processes and diseases.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a cyklin-dependentní kinasa 9 $x antagonisté a inhibitory $x metabolismus $7 D042863
- 650 _2
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x enzymologie $x patologie $7 D007249
- 650 _2
- $a nádory $x farmakoterapie $x enzymologie $7 D009369
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Baumli, Sonja
- 700 1_
- $a Fürst, Robert
- 773 0_
- $w MED00007893 $t Current pharmaceutical design $x 1873-4286 $g Roč. 18, č. 20 (2012), s. 2883-90
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22571657 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130108 $b ABA008
- 991 __
- $a 20130109113259 $b ABA008
- 999 __
- $a ok $b bmc $g 963612 $s 798994
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 18 $c 20 $d 2883-90 $i 1873-4286 $m Current pharmaceutical design $n Curr Pharm Des $x MED00007893
- LZP __
- $a Pubmed-20130108
